LUMICKS Revenue and Competitors

Amsterdam, Netherlands



Total Funding



Estimated Revenue & Valuation

  • LUMICKS's estimated annual revenue is currently $43.4M per year.(i)
  • LUMICKS's estimated revenue per employee is $154,000

Employee Data

  • LUMICKS has 282 Employees.(i)
  • LUMICKS grew their employee count by -2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

LUMICKS brings to market revolutionary single-molecule technologies that enable for the first time visualization of molecular interactions and acoustic manipulation of biomolecules. These breakthroughs are allowing scientists to understand life to the smallest detail, which is critical for cancer research and drug development. Current single-molecule techniques allow scientists to achieve only partial understanding of complex biological processes. With LUMICKS groundbreaking optical tweezer-fluorescence microscopy, scientists are now able to visualize and measure mechanical properties of biomolecular complexes in real time, revealing the complete picture. Manipulation, force measurements and visualization of these complexes, for example DNA-protein interactions, are performed simultaneously, which allows correlation of mechanical properties to the number, location and conformational state of proteins bound to DNA. LUMICKS provides ready-to-use instrumentation for single-molecule visualization, acoustic manipulation of biomolecules and microfluidic flow systems, allowing scientists to focus on their experiments and breakthrough science.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %






2022-04-13 - New Customer Installation of LUMICKS' z-Movi® Cell Avidity ...

AMSTERDAM, April 21, 2022 /PRNewswire/ -- LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule...

2022-03-30 - LUMICKS Strengthens its Innovative C-Trap® Solution with ...

LUMICKS is a leading life science tools company that develops equipment for Dynamic Single-Molecule and Cell Avidity analysis, two rapidly...

2021-04-19 - Amsterdam's Lumicks picks up $93M

Lumicks, a developer of single-molecule analysis technologies for cancer research and immunotherapy, has raised a $93 million Series D. Farallon Capital Management and Lauxera Capital Partners led the round, which the startup will use for research and development and to invest in its commercial ...

2021-04-16 - Amsterdam-based Lumicks raises €77.6M to provide instruments to reveal unique molecular, cellular interactions

With an exponential increase in the rate of progress in biological research, the demand to understand how biological processes occur at a molecular level is becoming increasingly important. And, according to Amsterdam-based Lumicks, it wants to make a difference by unlocking the power of Dynamic ...

2021-04-16 - Lumicks Raises $93M in Series D Financing

Lumicks, an Amsterdam, The Netherlands-based life science tools company that develops innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, closed a $93m Series D funding. The round was led by new investors Farallon Capital Management and Lauxera Capital Partners, with par ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding